Skip to main content

Table 4 Change in number of virus-free patients from visit 1 to visit 2 in ITT and PP population

From: Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

Patients Group Virus acquired Virus lost Significance
ITT (n = 236) Placebo (n = 120) 11 (9%) 18 (15%) n.s.
  Carrageenan (n = 116) 4 (3%) 27 (23%) p < 0.001
PP (n = 174) Placebo (n = 87) 5 (6%) 12 (14%) n.s.
  Carrageenan (n = 87) 3 (3%) 20 (23%) p < 0.001
  1. McNemar test within-group comparison.